Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 14,147 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Nov 9, 2026, 9:05 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT01980888
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Fullerton, California • La Jolla, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Nov 9, 2026, 9:05 AM EST
Completed Not applicable Interventional Results available

CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention

NCT03584386
View directory record Official record
Conditions
Suicide
Interventions
Jaspr, Jaspr-at-Home (JAH)
Device
Lead sponsor
Evidence-Based Practice Institute, Seattle, WA
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570
View directory record Official record
Conditions
Functional Constipation in Children Ages 6-17 Years
Interventions
Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

NCT00409851
View directory record Official record
Conditions
Hypertension
Interventions
valsartan+amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 2 Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

NCT00378131
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291, placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
17
States / cities
Glendale, Arizona • Encinitas, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional Results available

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03834753
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo
Drug · Device · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants

NCT01202760
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
77
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Nov 9, 2026, 9:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction

NCT05012982
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
AirBand, uninflated AirBand
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Milford, Connecticut • North Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients

NCT00598559
View directory record Official record
Conditions
Acute Pain, Fever
Interventions
IV Acetaminophen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 85 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Arcadia, California • Glendale, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Nov 9, 2026, 9:05 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480
View directory record Official record
Conditions
SLE
Interventions
Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
48
States / cities
Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NCT03572062
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Formulation A, Formulation B, Formulation C, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 3 Interventional

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

NCT00543374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, PROCHYMAL adult human mesenchymal stem cells
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
53
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

NCT03800420
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 2 Interventional

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

NCT01465282
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
CT327 0.05%, CT327 0.1%, CT327 0.5%, Placebo
Drug
Lead sponsor
Creabilis SA
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Hotsprings, Arkansas • San Ramon, California • Bay City, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Nov 9, 2026, 9:05 AM EST
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

NCT07765888
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Not listed Not applicable Interventional

Pilot Testing Decision Making in Aging and Dementia for Autonomy Program in Nursing Homes

NCT05618678
View directory record Official record
Conditions
Dementia, Staff Attitude, Nurse's Role, Nursing Homes
Interventions
DIGNITY, Infection Control
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Nov 9, 2026, 9:05 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

NCT07219589
View directory record Official record
Conditions
Obesity, Obese
Interventions
HM17321, Placebo of HM17321
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 9, 2026, 9:05 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Nov 9, 2026, 9:05 AM EST